Sub-acute Safety and Efficacy Evaluation of Single versus Double Treatment Cycles of a Monopolar Radiofrequency Catheter-Based Renal Nerve Ablation and its Chronic Evolution in a Large Animal Model

Bradley Hubbard, Atsushi Sakaoka, Irena Brants, Krista Dillon, Dane Brady, Serge Rousselle, Chandan Devireddy, Felix Mahfoud, Armando Tellez


Aims:We aimed to evaluate the transcatheter renal denervation(RDN) effects delivered by a mono-electrode catheter in a large animal model including safety implications of delivery of one cycle versus two cycles of ablations.

Methods and Results:18 animals underwent bilateral RDN; 4 untreated naïve swine were enrolled as controls for norepinephrine levels(NE) only. Animals recieved 120-second (follow up-7,30 and 90 days) or 240-second cycles ablations (follow up-7 days). Norepinephrine evaluation, histology and immunohistochemistry evaluation was performed. No luminal obstruction was observed at follow up. A 70% decrease in NE levels (76.68±57.87ng/g) was observed at 7 days, 81% at 30 days(49.05±45.81ng/g), and 51% at 90 days(12.7±73.2 ng/g) compared to naïve controls(254.1±54.1ng/g;p<0.05). Histologically, the thermal effect extended to a complete circumferential involvement with a depth ~8mm. The primary histological feature at 7 days was nerve necrosis and distal atrophy; at 30 days, necrosis was replaced by healing changes of fibrosis. Neuromatous regeneration was apparent at 30 days at RF treated levels. At 90 days these features progressed to become more conspicuous. There were no appreciable differences in depth and circumferential extent of RF injury between one and two cycle treatment groups.

Conclusion:RDN performed with a mono-electrode catheter (Iberis) appears to be safe following single or double-cycle RF ablation.NE decrease following RDN was demonstrated at 7, 30, and 90 days compared to naïve controls, suggesting efficient nerve ablation with the device as intended for human use.

Full Text:



Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol. 2000;35:S1–7.

Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–1281.

Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–1401.

Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D’Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O’Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators. 12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension: The SYMPLICITY HTN-3 Trial. J Am Coll Cardiol. 2015;65:1314–1321.

Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O’Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219–227.

Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens JASH. 2014;8:593–598.

Epstein M, de Marchena E. Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the “end of the road” for renal denervation? J Am Soc Hypertens JASH. 2015;9:140–149.

Schmieder RE. Hypertension: How should data from SYMPLICITY HTN-3 be interpreted? Nat Rev Cardiol. 2014;11:375–376.

Lüscher TF, Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? Eur Heart J. 2014;35:1706–1711.

Mahfoud F, Lüscher TF. Renal denervation: symply trapped by complexity? Eur Heart J. 2015;36:199–202.

Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand P-Y, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin P-F, Chatellier G, the Renal Denervation for Hypertension (DENERHTN) investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;

Jiang X-J, Dong H, Liang T, Zou Y-B, Xu B, Gao R-L. First-in-man report of a novel dedicated radiofrequency catheter for renal denervation via the transulnar approach. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2013;9:684–686.

Honton B, Pathak A, Sauguet A, Fajadet J. First report of transradial renal denervation with the dedicated radiofrequency IberisTM catheter. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2014;9:1385–1388.

Rousselle, Serge D., Brants, Irena K., Sakaoka, Atsushi, Hubbard, Bradley, Jackson, Nicolette D., Wicks, Joan R., Dillon, Krista N., L.A. Naiche, Hart, Randy, Garza, Javier A., Tellez, Armando. Neuromatous regeneration as a nerve response after catheter-based renal denervation therapy in a large animal model: immunohistochemical study. Circ Cardiovasc Interv. 2015;8.

Jacobson RD, Virág I, Skene JH. A protein associated with axon growth, GAP-43, is widely distributed and developmentally regulated in rat CNS. J Neurosci Off J Soc Neurosci. 1986;6:1843–1855.

Harding DI, Greensmith L, Mason M, Anderson PN, Vrbová G. Overexpression of GAP-43 induces prolonged sprouting and causes death of adult motoneurons. Eur J Neurosci. 1999;11:2237–2242.

Rippy MK, Zarins D, Barman NC, Wu A, Duncan KL, Zarins CK. Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol Off J Ger Card Soc. 2011;100:1095–1101.

Sakakura K, Tunev S, Yahagi K, O’Brien AJ, Ladich E, Kolodgie FD, Melder RJ, Joner M, Virmani R. Comparison of histopathologic analysis following renal sympathetic denervation over multiple time points. Circ Cardiovasc Interv. 2015;8:e001813.

DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245–253.

Cohen-Mazor M, Mathur P, Stanley JRL, Mendelsohn FO, Lee H, Baird R, Zani BG, Markham PM, Rocha-Singh K. Evaluation of renal nerve morphological changes and norepinephrine levels following treatment with novel bipolar radiofrequency delivery systems in a porcine model. J Hypertens. 2014;32:1678–1691; discussion 1691–1692.

Kovacic U, Zele T, Mars T, Sketelj J, Bajrović FF. Aging impairs collateral sprouting of nociceptive axons in the rat. Neurobiol Aging. 2010;31:339–350.

Nomura G, Kurosaki M, Takabatake T, Kibe Y, Takeuchi J. Reinnervation and renin release after unilateral renal denervation in the dog. J Appl Physiol. 1972;33:649–655.

Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP, May CN. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension. 2015;65:393–400.

Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I, Strandgaard S. The transplanted human kidney does not achieve functional reinnervation. Clin Sci Lond Engl 1979. 1994;87:13–20.

Tzafriri AR, Mahfoud F, Keating JH, Markham PM, Spognardi A, Wong G, Fuimaono K, Böhm M, Edelman ER. Innervation patterns may limit response to endovascular renal denervation. J Am Coll Cardiol. 2014;64:1079–1087.

Tzafriri AR, Keating JH, Markham PM, Spognardi A-M, L Stanley JR, Wong G, Zani BG, Highsmith D, O’Fallon P, Fuimaono K, Mahfoud F, Edelman ER. Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension. Sci Transl Med. 2015;7:285ra65.

Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622–629.

Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35:1752–1759.

Wilson GJ, Winsor-Hines D, Tunstall RR, Wilson PD, Hawley SP, Eskandarian M, Svajger G, Davis L, Bankes J, Huibregtse BA. Bipolar multi-electrode balloon catheter radiofrequency renal denervation with the Vessix system: preclinical safety evaluation. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2015;10:1239–1246.

Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2012;8:57–61.

Ji M, Shen L, Wu Y-Z, Yao Z-F, Yin J-S, Chen J-H, Jia J-G, Qiao L-J, Liu P, Ge J-B. Short-term safety and efficiency of cryoablation for renal sympathetic denervation in a swine model. Chin Med J (Engl). 2015;128:790–794.

Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, Lüscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, Wijns W, Zeller T, Schmieder RE. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219-27. doi: 10.1093/eurheartj/ehv192

Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2 DOI: 10.17987/icfj.v2i1.4.



  • There are currently no refbacks.

Copyright (c) 2016 Bradley Hubbard, Atsushi Sakaoka, Irena Brants, Krista Dillon, Dane Brady, Serge Rousselle, Chandan Devireddy, Felix Mahfoud, Armando Tellez

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN: 2518-6140 (on-line version)